4 reports of this reaction
2.8% of all ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY reports
#5 most reported adverse reaction
ERYTHEMA is the #5 most commonly reported adverse reaction for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, manufactured by The Procter & Gamble Manufacturing Company. There are 4 FDA adverse event reports linking ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY to ERYTHEMA. This represents approximately 2.8% of all 144 adverse event reports for this drug.
Patients taking ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY who experience erythema should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ERYTHEMA is a less commonly reported adverse event for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, but still significant enough to appear in the safety profile.
In addition to erythema, the following adverse reactions have been reported for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY:
The following drugs have also been linked to erythema in FDA adverse event reports:
ERYTHEMA has been reported as an adverse event in 4 FDA reports for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY. This does not prove causation, but indicates an association observed in post-market surveillance data.
ERYTHEMA accounts for approximately 2.8% of all adverse event reports for ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, making it a notable side effect.
If you experience erythema while taking ALUMINUM ZIRCONIUM TETRACHLOROHYDREX GLY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.